14 results about "Hippocampal neuron" patented technology

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The application discloses an antiepileptic preparation preparation method and application of a micro ribonucleic acid 145b targeting agent, and relates to the technical field of biological medicine. The method comprises the following steps: constructing a neuron-specific recombinant adeno-associated virus plasmid vector, wherein the vector comprises a neuron-specific promoter hSyn, a reporter gene, an enhancer, and a functional nucleic acid sequence for targeting and inhibiting micro ribonucleic acid 145b; using an adeno-associated virus packaging system to transfect the vector to a packaging cell for virus packaging; collecting a lysis solution and separating out a recombinant adeno-associated virus particle through a purification process; and resuspending the virus particle to obtain a preparation. The application specifically down-regulates the miR-145b level in hippocampal neurons, releases the inhibition of the Kcnq3 potassium ion channel, further up-regulates the Kcnq3 expression, restores the M current, and reduces the neuron excitability from a molecular mechanism.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application belongs to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine supramolecular nanoparticle, which is prepared from Uncaria as a raw medicinal material, is extracted by heating reflux with 68-72% ethanol, is filtered, and is dried after being dialyzed after being dispersed in pure water, centrifuged, resuspended, and centrifuged again. The traditional Chinese medicine supramolecular nanoparticle has uniform particle size, a narrow particle size distribution, and high stability. The nanoparticle has obvious anti-nerve oxidation and obvious nerve protection effects according to in-vitro cell activity detection. The nanoparticle has good in-vivo nerve protection effect, can improve memory impairment and cognitive impairment, and can prevent hippocampal neuron reduction. Compared with Uncaria effective parts, the effective administration dose of the traditional Chinese medicine supramolecular nanoparticle is obviously reduced. The application also discloses a use of the traditional Chinese medicine supramolecular nanoparticle in preparation of a medicine for treating nervous system diseases.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

This invention provides an application of Pulsatilla Decoction in the preparation of drugs for treating cognitive impairment. It significantly improves spatial learning and memory, recognition memory, and anxiety-depression-like behaviors in model mice, while increasing cerebral blood flow, reducing hippocampal neuronal damage, and effectively regulating the levels of neurotransmitters such as tryptophan, 5-HT, dopamine, and GABA in the brain. This formula exerts a central protective effect while alleviating intestinal inflammation, demonstrating the dual regulatory advantage of the gut-brain axis. Furthermore, its active ingredient, Pulsatilla saponin B4, also has the effect of improving cognitive function. This invention provides a scientific basis for the "repurposing" of classic formulas, possessing clear efficacy, good safety, and mature preparation technology, and has good prospects for clinical translation.

This invention discloses a 3-hydroxypyridinone derivative, its preparation method, and its applications. This 3-hydroxypyridinone derivative, through structural modification of the 3-hydroxypyridinone core, significantly enhances its anti-ferroptosis activity against hippocampal neurons in HT-22 mice. In vitro experiments show that its inhibitory effect on ferroptosis is more than twice that of the positive control deferoxone. Furthermore, the 3-hydroxypyridinone derivative can also chelate Fe... 3+ To alleviate iron-mediated Aβ 1‑42 Protein aggregation and its cytotoxicity. This invention also provides synthetic routes, purification methods, and in vitro activity evaluation systems for 3-hydroxypyridinone derivatives, offering structural optimization strategies and candidate compounds for the development of drugs targeting iron metabolism disorders.

This invention discloses the application of Polygonatum odoratum carbon quantum dots (PC-CQDs) in the preparation of drugs for treating vascular dementia, belonging to the field of pharmaceutical technology. This invention is the first to apply PC-CQDs to the treatment of vascular dementia. Morris water maze test and hippocampal histopathological analysis confirmed that PC-CQDs can significantly improve spatial learning and memory abilities in VaD rats, protect hippocampal neurons, and exhibit good biocompatibility. This invention provides a new drug option for the treatment of vascular dementia, possessing significant clinical application value and broad market prospects.

This invention discloses the application of GGCX in the preparation of reagents for the diagnosis or auxiliary diagnosis of ischemic stroke. First, a six-layer progressive genetic evidence system was constructed to confirm that upregulation of gamma-glutamyl carboxylase (GGCX) is a protective factor against ischemic stroke, and that the protective effect is subtype-specific. Second, a diagnostic model was constructed based on peripheral blood GGCX expression data. Finally, the significant downregulation of GGCX under ischemic conditions was verified through three levels: clinical sample qPCR detection, tMCAO / R animal model, and primary hippocampal neuronal OGD / R cell model, with an AUC value of 0.889 in the clinical validation cohort. This invention provides a reliable approach for the early auxiliary diagnosis of ischemic stroke based on the peripheral blood biomarker GGCX. It has clear clinical value and significance for improving the early diagnosis rate of ischemic stroke and shortening the time from onset to treatment.

The application belongs to the technical field of biological medicine, and discloses a nano regulator for treating cerebral hemorrhage, a preparation method and application thereof. First, a DNA nanoflower containing a hybridization site is prepared based on RCA technology, and is hybridized with a T structure containing a target transferrin receptor, so that the obtained carrier has the ability to cross the blood-brain barrier and gather at the damage site. Then, the nano regulator TNF@Gin is obtained by loading ginkgo flavones through non-covalent interaction. The obtained nano regulator can promote the polarization of microglial cells to the anti-inflammatory M2 phenotype, thereby reducing the level of pro-inflammatory factors and relieving excessive inflammatory response. In addition, the nano regulator can effectively clear ROS and Nrf2 / GPX4 signal pathway, and inhibit the ferroptosis of hippocampal neuron cells. The nano regulator shows high and safe treatment results, and provides a new strategy for treating cerebral hemorrhage.

This invention provides lactylated PRDX5 protein, its products, and applications, belonging to the field of biomedical technology. This invention reveals the crucial role of PRDX5 K71 site lactylation modification in the pathological process of COPD, showing abnormally elevated levels of lactylation in hippocampal neurons of COPD mice, which is closely related to the occurrence and development of cognitive impairment in mice. Simultaneously, it provides a specific intervention protocol targeting this site. Stereoscopic injection of recombinant adeno-associated virus PRDX5 K71R mutant reduces or blocks the likelihood of lactylation modification at the K71 site, effectively improving learning, memory, and spatial orientation abilities in COPD mice. This provides new molecular targets and experimental evidence for the study of the mechanisms of cognitive impairment and targeted prevention and treatment.

This invention provides the application of Tongren Niuhuang Qingxin Pill in the preparation of drugs for the prevention and treatment of acute mountain sickness, relating to the field of pharmaceutical formulation technology. In the application of Tongren Niuhuang Qingxin Pill in the preparation of drugs for the prevention and treatment of acute mountain sickness, it improves mitochondrial structure and function by regulating the expression of nuclear respiratory factor Nrf1 protein, protecting hippocampal neurons, and enhancing the learning and memory abilities of model rats. It can also improve brain tissue water homeostasis in rats with acute mountain sickness through anti-oxidative stress, thereby achieving a preventive and therapeutic effect on acute mountain sickness in rats.